Insilico Medicine Nominates ISM9546 as Preclinical Candidate – Oral, Peripherally Restricted VAV1 Molecular Glue Degrader Targets IBD and Rheumatoid Arthritis
CompanyR&D

Insilico Medicine Nominates ISM9546 as Preclinical Candidate – Oral, Peripherally Restricted VAV1 Molecular Glue Degrader Targets IBD and Rheumatoid Arthritis

Insilico Medicine (HKG: 3696), an AI‑powered drug discovery company, announced the nomination of ISM9546 as a preclinical candidate (PCC) – an innovative, oral, peripherally restricted VAV1 molecular glue degrader with…

Lepu Scientech's MemoCarna Oxide Film Single‑Rivet PFO Occluder Approved for Market Launch by NMPA – Novel Design Targets Residual Shunts in Patent Foramen Ovale Closure
CompanyMedical Device

Lepu Scientech’s MemoCarna Oxide Film Single‑Rivet PFO Occluder Approved for Market Launch by NMPA – Novel Design Targets Residual Shunts in Patent Foramen Ovale Closure

CompanyDrug

Luzhu Biotech’s Self‑Developed Recombinant RSV Vaccine Candidate Approved for Clinical Trials by NMPA – Pre‑F Protein Antigen Advances Toward Prevention of RSV Lower Respiratory Tract Disease

BrightGene's BGM0504 Approved for Clinical Trials in China – In‑House Dual GLP‑1/GIP Receptor Agonist Advances Toward Adult Type 2 Diabetes
CompanyDrug

BrightGene’s BGM0504 Approved for Clinical Trials in China – In‑House Dual GLP‑1/GIP Receptor Agonist Advances Toward Adult Type 2 Diabetes

Beijing Balance Medical's Transcatheter Pulmonary Valve System Wins NMPA Approval – Third Innovative‑Device Clearance Redefines TPVR with Transthoracic Remodeling Approach
CompanyMedical Device

Beijing Balance Medical’s Transcatheter Pulmonary Valve System Wins NMPA Approval – Third Innovative‑Device Clearance Redefines TPVR with Transthoracic Remodeling Approach

- Advertisement -
Ad image
Rainmed Medical Reports 41% Revenue Growth in 2026 Interim Results – caFFR Consumables Drive Gross Margin to 63.2% as Losses Narrow 31%
Company

Rainmed Medical Reports 41% Revenue Growth in 2026 Interim Results – caFFR Consumables Drive Gross Margin to 63.2% as Losses Narrow 31%

China's CDE Slates Highlightll's Ginocitinib (TLL‑018) for Priority Review – First Domestic Dual‑Target JAK1/TYK2 Inhibitor for Rheumatoid Arthritis
CompanyDrug

China’s CDE Slates Highlightll’s Ginocitinib (TLL‑018) for Priority Review – First Domestic Dual‑Target JAK1/TYK2 Inhibitor for Rheumatoid Arthritis

InnoCare Strikes Strategic Research and Licensing Deal With Eli Lilly – Up to USD 100 Million Upfront and USD 3.25 Billion in Milestones for Up to Five Innovative Target Programs
CompanyDeals

InnoCare Strikes Strategic Research and Licensing Deal With Eli Lilly – Up to USD 100 Million Upfront and USD 3.25 Billion in Milestones for Up to Five Innovative Target Programs

Sanyou Bio and NovoCodex Forge Strategic ADC Partnership – AI‑Driven Antibody Discovery Meets Site‑Specific Conjugation for Dual‑Targeting, Dual‑Payload Programs
CompanyDeals

Sanyou Bio and NovoCodex Forge Strategic ADC Partnership – AI‑Driven Antibody Discovery Meets Site‑Specific Conjugation for Dual‑Targeting, Dual‑Payload Programs

China Orders Whole‑Class Listing of "Orphine‑Type Substances" in Non‑Medicinal Narcotic and Psychotropic Catalogue – Tri‑Agency Control Takes Effect 1 October 2026
Policy / Regulatory

China Orders Whole‑Class Listing of “Orphine‑Type Substances” in Non‑Medicinal Narcotic and Psychotropic Catalogue – Tri‑Agency Control Takes Effect 1 October 2026

Shanghai RAAS to Acquire 100% of Boehringer Ingelheim China Investment Entity for Up to RMB 20 Million – Deal Secures End‑to‑End In‑House Control of First‑in‑Class SR604 Injection
CompanyDeals

Shanghai RAAS to Acquire 100% of Boehringer Ingelheim China Investment Entity for Up to RMB 20 Million – Deal Secures End‑to‑End In‑House Control of First‑in‑Class SR604 Injection

Roche Reports Positive Phase III Interim Results for Sefaxersen in IgA Nephropathy – First mRNA‑Targeted Therapy Meets Primary Proteinuria Endpoint in IMAgINATION
CompanyDrug

Roche Reports Positive Phase III Interim Results for Sefaxersen in IgA Nephropathy – First mRNA‑Targeted Therapy Meets Primary Proteinuria Endpoint in IMAgINATION

Sunflower Pharmaceutical to Acquire 100% of Dongxu Pharmaceutical for RMB 780,000 – Deal Targets Multi‑Line Marketing Network Efficiency
CompanyDeals

Sunflower Pharmaceutical to Acquire 100% of Dongxu Pharmaceutical for RMB 780,000 – Deal Targets Multi‑Line Marketing Network Efficiency

Astellas Doses First Patient in Phase 3 Trial of Setidegrasib Versus Docetaxel – First Pivotal Test of a KRAS G12D Degrader in Pretreated NSCLC
CompanyDrug

Astellas Doses First Patient in Phase 3 Trial of Setidegrasib Versus Docetaxel – First Pivotal Test of a KRAS G12D Degrader in Pretreated NSCLC

Henlius Secures Global Exclusive License Deal With Amberstone Biosciences – Conditionally Activated TCEs for Solid Tumors Built on the pH‑Sensitive T‑MATE Platform
CompanyDeals

Henlius Secures Global Exclusive License Deal With Amberstone Biosciences – Conditionally Activated TCEs for Solid Tumors Built on the pH‑Sensitive T‑MATE Platform

European Commission Approves AbbVie's RINVOQ (Upadacitinib) for Juvenile Idiopathic Arthritis – Ninth EU Indication for the JAK Inhibitor
CompanyDrug

European Commission Approves AbbVie’s RINVOQ (Upadacitinib) for Juvenile Idiopathic Arthritis – Ninth EU Indication for the JAK Inhibitor

Novo Nordisk Says 1.5 Million Patients Are Now on the Oral Wegovy Pill – Capacity to Expand 10‑Fold by 2030 as Sales Growth Outpaces Eli Lilly's Foundayo
Company

Novo Nordisk Says 1.5 Million Patients Are Now on the Oral Wegovy Pill – Capacity to Expand 10‑Fold by 2030 as Sales Growth Outpaces Eli Lilly’s Foundayo

Show More